2096 Stock Overview Engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. More details
Rewards Risk Analysis No risks detected for 2096 from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Simcere Pharmaceutical Group Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Simcere Pharmaceutical Group Historical stock prices Current Share Price HK$6.75 52 Week High HK$7.70 52 Week Low HK$4.94 Beta 0.44 1 Month Change 2.12% 3 Month Change 11.57% 1 Year Change 6.80% 3 Year Change -28.19% 5 Year Change n/a Change since IPO -38.52%
Recent News & Updates
Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration Dec 02
Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List Nov 28
Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable Nov 21
Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference Oct 30
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Sep 29
Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration Sep 05 See more updates
Simcere Pharmaceutical Group Limited Announces Approval for Marketing of Sanbexin Sublingual Tablets in China by the National Medical Products Administration Dec 02
Simcere Pharmaceutical Group Limited Announces Inclusion of Three Innovative Drugs, Cosela, Enlituo and Sanbexin, in the New National Reimbursement Drug List Nov 28
Simcere Pharmaceutical Group Limited's (HKG:2096) P/S Still Appears To Be Reasonable Nov 21
Simcere Pharmaceuticals Group Ltd. Announces That A New Clinical Study with Major Clinical Findings Regarding Sanbexin (Edaravone and Dexborneol Concentrated Solution for Injection) Has Been Published At the 16th World Stroke Conference Oct 30
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Sep 29
Simcere Pharmaceuticals Group Ltd. Announces Breakthrough Therapy Designation for Sanbexin Sublingual Tablets Granted by the United States Food and Drug Administration Sep 05
First half 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.87 in 1H 2023) Aug 24
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by the National Medical Products Administration Aug 22
Simcere Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Aug 09
Now 22% overvalued Aug 03
Simcere Pharmaceutical Group Limited (HKG:2096) Not Lagging Market On Growth Or Pricing Jul 29
Simcere Pharmaceutical Group Limited Announces New Drug Application of Quviviq (Daridorexant Hydrochloride Tablets) Has Been Accepted by the National Medical Products Administration Jul 17
Simcere Pharmaceutical Group Limited Announces Regular Approval of Xiannuoxin, an Anti-Sars-Cov-2 Innovative Drug Jul 11
Co-Founder recently sold HK$1.2m worth of stock Jun 28
Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China Jun 25 Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback for 260,976,161 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2024. Jun 20
Upcoming dividend of CN¥0.16 per share Jun 11
Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China Jun 01
Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong May 23
Why Simcere Pharmaceutical Group's (HKG:2096) Shaky Earnings Are Just The Beginning Of Its Problems May 01
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 26
Consensus revenue estimates fall by 14% Mar 22
Dividend of CN¥0.16 announced Mar 22 Simcere Pharmaceutical Group Limited, Annual General Meeting, Jun 14, 2024
Consensus EPS estimates fall by 37% Mar 16
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China Mar 16
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration Mar 13
Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500 Mar 12
Simcere Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023 Feb 20
Consensus EPS estimates fall by 35% Feb 20
Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19 Jan 19
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0501 Tablets Jan 12
Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The Market Dec 29
Simcere Pharmaceutical Group Limited Announces Localization Application of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China Dec 27
Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug for SIM0501 (An Usp1 Small-Molecule Inhibitor) Issued by U.S. Food and Drug Administration Dec 04
Simcere Pharmaceutical Group Limited and Neurodawn Pharmaceutical Co., Ltd. Obtains Clinical Trial Approval Issued by the National Medical Products Administration Nov 30
Simcere Pharmaceutical Group Limited Announces Approval of COSELA (Trilaciclib Hydrochloride for Injection) Approved by the National Medical Products Administration of China Oct 31
Simcere Pharmaceutical Group Limited Announces the Clinical Trial Approval for New Indication of Sim0237 for Injection (Anti-Pd-L1/IL-15 Bispecific Antibody) Issued by the National Medical Products Administration Oct 17
Co-Founder recently bought HK$1.2m worth of stock Aug 31
Need To Know: Analysts Just Made A Substantial Cut To Their Simcere Pharmaceutical Group Limited (HKG:2096) Estimates Aug 28
Consensus revenue estimates fall by 22% Aug 28
First half 2023 earnings released: EPS: CN¥0.87 (vs CN¥0.024 in 1H 2022) Aug 22
Simcere Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 21, 2023 Aug 10
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration Jul 28
Simcere Pharmaceutical Group Limited Obtains Clinical Trial Approval Issued by National Medical Products Administration Jul 23
Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023. Jul 01
Simcere Pharmaceutical Group Limited (SEHK:2096) commences an Equity Buyback Plan for 266,404,561 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023. Jun 30
Co-Founder recently sold HK$710k worth of stock Jun 30
New minor risk - Insider selling Jun 23
Co-Founder recently sold HK$2.3m worth of stock Jun 21
Simcere Pharmaceutical Group Limited Approves Final Cash Dividend for the Year Ended December 31, 2022, Payable on 12 July 2023 Jun 16
Co-Founder recently bought HK$1.5m worth of stock Jun 15
Upcoming dividend of CN¥0.16 per share at 2.3% yield Jun 12
Are Investors Undervaluing Simcere Pharmaceutical Group Limited (HKG:2096) By 40%? Jun 03
Co-Founder recently sold HK$3.1m worth of stock Apr 30
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 19
Investor sentiment improves as stock rises 15% Apr 13
Consensus revenue estimates fall by 13% Apr 11
Analysts Just Shaved Their Simcere Pharmaceutical Group Limited (HKG:2096) Forecasts Dramatically Apr 06
Now 23% undervalued Feb 06
Simcere Pharmaceutical Group Limited Announces Conditional Approval for Marketing in China of Anti-Sars-Cov-2 Innovative Drug Xiannuoxin Tm Granted by the National Medical Products Administration Jan 30
Simcere Pharmaceutical Group Limited Announces Appointment Wang Xi as an Executive Director and the Appointment of Sung Ka Woon as an Independent Non-Executive Director Jan 19
Investor sentiment deteriorated over the past week Jan 19
Simcere Pharmaceutical Group Limited Announces Acceptance of New Drug Application of Anti-SARS-CoV-2 Innovative Drug Xiannuoxin (Simnotrelvir Tablets/Ritonavir Tablets (Co-Packaged)) by the National Medical Products Administration Jan 17
Now 24% undervalued Jan 17
Co-Founder recently bought HK$7.9m worth of stock Jan 11
Estimating The Intrinsic Value Of Simcere Pharmaceutical Group Limited (HKG:2096) Jan 10 Simcere Pharmaceutical Group Limited Appoints Mr. Tang Renhong as the Chairman of the Board of Directors and Chief Executive Officer of Simcere Zaiming Pharmaceutical Co., Ltd., with Effect from January 1, 2023
Simcere Pharmaceutical Group Limited Announces - the Clinical Trial Approval for SIM0348 Injection (Humanized TIGIT/PVRIG Bispecific Antibody) Issued by the National Medical Products Administration Dec 30
Now 20% undervalued Dec 30
Investor sentiment improved over the past week Dec 29
Simcere Pharmaceutical Group Announces Phase II/III Clinical Trial of Its 3Cl-Targeting anti-SARS-CoV-2 Drug Candidate Complete All Patients Enrollment Dec 21
Simcere Pharmaceutical Group Limited Announces A Phase II/III Clinical Study of Anti-Sars-COV-2 Drug Candidate XIANNUOXIN (SIM0417) Complete All Patients Enrollment Dec 19
Investor sentiment deteriorated over the past week Dec 06
Simcere Pharmaceutical Group Limited Announces A Multi-Center, Randomized, Double-Blind, Parallel and Placebo-Controlled Phase III Clinical Study Dec 03
Insufficient new directors Nov 16
Simcere Pharmaceutical Group Limited Announces Executive Changes Nov 10
Investor sentiment improved over the past week Nov 02
Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug Application Oct 28
Investor sentiment improved over the past week Oct 14
First half 2022 earnings released: EPS: CN¥0.024 (vs CN¥0.21 in 1H 2021) Oct 01
Consensus EPS estimates fall by 20% Sep 07
Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP Sep 07
Simcere Pharmaceutical Group Limited Appoints Tamas Oravecz as SVP Sep 06
First half 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.21 in 1H 2021) Sep 01
Simcere Pharmaceutical Group Limited Announces Executive and Committee Changes Sep 01
Simcere Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 31, 2022 Aug 20
With EPS Growth And More, Simcere Pharmaceutical Group (HKG:2096) Makes An Interesting Case Aug 16
Simcere Pharmaceutical Group Limited Provides Earnings Guidance for the Six Months Ended June 30, 2022 Aug 02
Cosela, the World's First Comprehensive Myeloprotection Drug Against Chemotherapy Damage, Wins Approval in China Jul 19
Simcere Pharmaceutical Group Limited Announces Conditional Marketing of COSELA (Trilaciclib Hydrochloride for Injection) in China by the National Medical Products Administration Jul 14
Simcere Pharmaceutical Group (HKG:2096) Has Announced A Dividend Of HK$0.18 Jun 27
Simcere Pharmaceutical Group Limited Declares Final Dividend for the Year Ended December 31, 2021, Payable on July 15, 2022 Jun 25 Shareholder Returns 2096 HK Pharmaceuticals HK Market 7D -6.4% -1.9% -0.5% 1Y 6.8% -3.9% 19.9%
See full shareholder returns
Return vs Market: 2096 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility Is 2096's price volatile compared to industry and market? 2096 volatility 2096 Average Weekly Movement 7.6% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
Stable Share Price: 2096 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2096's weekly volatility (8%) has been stable over the past year.
About the Company Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets.
Show more Simcere Pharmaceutical Group Limited Fundamentals Summary How do Simcere Pharmaceutical Group's earnings and revenue compare to its market cap? 2096 fundamental statistics Market cap HK$16.79b Earnings (TTM ) -HK$1.17b Revenue (TTM ) HK$6.76b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2096 income statement (TTM ) Revenue CN¥6.34b Cost of Revenue CN¥1.45b Gross Profit CN¥4.88b Other Expenses CN¥5.99b Earnings -CN¥1.10b
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.44 Gross Margin 77.05% Net Profit Margin -17.39% Debt/Equity Ratio 14.5%
How did 2096 perform over the long term?
See historical performance and comparison Dividends
2.5% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 06:20 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Simcere Pharmaceutical Group Limited is covered by 16 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Sharon Shi BOCI Research Ltd. Shaojing Tong BofA Global Research Bo Yu China International Capital Corporation Limited
Show 13 more analysts 
